Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/1998

01-10-1998 | ORIGINAL ARTICLE

Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer

Authors: Colleen J. Gilbert, William P. Petros, James Vredenburgh, Atif Hussein, Maureen Ross, Peter Rubin, Randy Fehdrau, Colleen Cavanaugh, Donald Berry, Craig McKinstry, William P. Peters

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/1998

Login to get access
Metadata
Title
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer
Authors
Colleen J. Gilbert
William P. Petros
James Vredenburgh
Atif Hussein
Maureen Ross
Peter Rubin
Randy Fehdrau
Colleen Cavanaugh
Donald Berry
Craig McKinstry
William P. Peters
Publication date
01-10-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050851

Other articles of this Issue 6/1998

Cancer Chemotherapy and Pharmacology 6/1998 Go to the issue

ORIGINAL ARTICLE

Lack of correlation of MRP and γ-glutamylcysteine synthetase overexpression with doxorubicin resistance due to increased apoptosis in SV40 large T-antigen-transformed human mesothelial cells

SHORT COMMUNICATIONS

Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration

ORIGINAL ARTICLE

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration

ORIGINAL ARTICLE

Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma

ORIGINAL ARTICLE

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors

ORIGINAL ARTICLE

Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits